A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 329 participants.

Also called NCT01717313

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 329 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01717313
  • EudraCT 2012-003626-24
Other papers using this trial's data
  • A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes Diabetes research and clinical practice, 2018-04 DOI, PubMed 29079379

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01717313. Randomized; triple masking; primary purpose treatment. Start 2012-12-05 (actual); primary completion 2015-06-19 (actual). Results posted on 2016-07-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Omarigliptin
Intervention (Drug)
Placebo to Omarigliptin
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo to metformin
Intervention (Drug)
Glimepiride
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01717313
Content hash
525254eaf3bcbe289abc2b5b886e040d611e4a42ce92d72ffaa17ef734dd3a83